CROs seem to have an irresistable magnetism for acquisitions or ‘mergers’.
This continuing attraction to add more and more services appears to be a fact of life in the Clinical Development Outsourcing world, leading to vital questions in the selection and ongoing management of suppliers such as
Does it increase or reduce choice?
Can you have too many offerings under the one CRO roof?
Are subsequent interactions easier or more complicated?
Does the CRO acquiring smaller, specialised suppliers end the independent spirit that made them effective?
With the reduced opportunities to meet F2F at conferences and share information on current market awareness, PCMG have launched a new initiative. We invite a CRO selected by the PCMG Committee that is ideally placed to provide their view on a major current outsourcing topic then respond to questions from the exclusively PCMG membership audience.
Following their recent acquisitions of Synteract and Illingworth Research, we are pleased to confirm that Alistair MacDonald, CEO of Syneos has agreed to step into the PCMG Spotlight. He will make the case for Syneos’ expansion and then answer YOUR concerns and queries with regard to CRO acquisitions and mergers.
Advance questions are welcomed – please either email us at email@example.com
or use the form below.
ARE CRO ACQUISITIONS FRIDGE MAGNET TROPHIES OR VALUE-ADDING SYNERGIES? MAKE YOUR VOICE HEARD!